• May 11, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a third quarter 2017 dividend payable to holders of the company’s common stock of $0.105 per share. The dividend is to be paid on Friday, Sept. 1, 2017, to holders of record on Thursday, June 15, 2017. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years ofmore...
  • May 11, 2017
    SHORT HILLS, N.J.--(BUSINESS WIRE)--Speaking to shareholders at the Zoetis Inc. (NYSE:ZTS) annual meeting today in Short Hills, N.J., Chief Executive Officer Juan Ramón Alaix discussed the company’s 2016 performance and strategies for continued growth as the leader in the global animal health industry. “In 2016, we delivered our fourth consecutive year of operational revenue growth and improved profitability since becoming an independent public company,” said Alaixmore...
  • May 10, 2017
    Zoetis Inc. today announced a plan to expand capacity at its Global Manufacturing and Supply facility in Kalamazoo, Mich.  Zoetis will install two new production lines and related operations to manufacture oral tablet and chewable medicines for companion animals. The company expects to add up to 45 manufacturing positions in the next three years.    “Kalamazoo is home to one of the largest and most important manufacturing sites in Zoetis’ Global Manufacturing and Supplymore...
  • May 9, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS), the global leader in animal health, today announced that it has been named one of America’s Best Midsize Employers by Forbes Magazine for the second year in a row. Zoetis is the only midsize company focused on animal health to make the list. “Zoetis is honored to once again be named one of America’s Best Employers by Forbes Magazine,” said Roxanne Lagano, Executive Vice President and Chief Humanmore...
  • May 8, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS), the largest global animal health company, announced it will receive a US$14.4 million grant from the Bill & Melinda Gates Foundation over the next three years to develop veterinary diagnostic networks and animal health infrastructure in Ethiopia, Nigeria and Uganda. The grant will enable Zoetis to develop veterinary laboratory networks and outreach services to increase the availability of localmore...
  • May 4, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2017 and reaffirmed its guidance for full year 2017. The company reported revenue of $1.2 billion for the first quarter of 2017, an increase of 6% compared with the first quarter of 2016. Net income for the first quarter of 2017 was $238 million, or $0.48 per diluted share, an increase of 17% on a reported basis. Adjusted net income1 formore...
  • May 2, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 17, 2017, in Las Vegas, Nev. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 4:00 p.m. ET (1:00 p.m. PT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visitingmore...
  • April 26, 2017
    ZAVENTEM, Belgium--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the company marketing authorization for Cytopoint (lokivetmab), the first monoclonal antibody (mAb) therapy approved in the European Union for veterinary use. Cytopoint is indicated to treat the clinical signs, including itching and inflammation, associated with atopic dermatitis in dogs of any age weighing 3 kilograms or more. Cytopoint targets andmore...
  • April 13, 2017
    PARSIPPANY, N.J. & TULLAMORE, Ireland--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) and Nexvet Biopharma plc (Nasdaq:NVET) today announced an agreement in which Zoetis, through a wholly owned subsidiary (“Zoetis Bidco”), will purchase Nexvet, an innovator in monoclonal antibody therapies for companion animals, for a purchase price of US$6.72 per share, representing an aggregate equity valuation of approximately US$85 million. The acquisition will strengthen Zoetis’ pipeline of solutions for chronicmore...
  • April 13, 2017
    PARSIPPANY, N.J. & TULLAMORE, Ireland--(BUSINESS WIRE)--COMPANY NAME: ZOETIS INC. HEADLINE: ZOETIS TO ACQUIRE NEXVET FOR US$85 MILLION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY RESTRICTED JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE 13 April 2017 ZOETIS TO ACQUIRE NEXVET FOR US$6.72 IN CASH PERmore...